ACE inhibitors and angiotensin receptor blockers have been shown to be effective in COVID-19, delaying SARS-CoV-2 binding by activating ACE2 and boosting angiotensin-1–7 availability [69,70]. The gene discussed is ACE2; the disease is COVID-19.